On the other side, ProMune® triggers a fivefold higher secretion of IL‐8, which rather promotes tumor growth through angiogenesis, and a threefold better maturation of pDC and stronger activation of B cells (indicated by CD86 up‐regulation, see Fig. 1d) while dSLIM® directly activates this cell population only to a minor extent. The gene discussed is CD86; the disease is neoplasm.